NEW YORK, March 2 (Reuters) - Drugmaker Pfizer Inc
said on Monday that it identified certain antiviral compounds it
had in development that have the potential to inhibit
coronaviruses and is engaging with a third party to screen the
compounds.
The company said it hopes to have the results from that
screening by the end of March and if any of the compounds are
successful, it would hope start testing them by the end of the
year.
Pfizer Chief Scientific Officer Mikael Dolsten was one of a
number of pharmaceutical executives who met with U.S. President
Trump at the White House on Monday.
(Reporting by Michael Erman; Editing by Sandra Maler)